# Programas de Trabalho e outras iniciativas
# A Saúde no Horizonte 2020

**Patrícia Calado**

# Depois desta apresentação tem duas opções:

**Entrar em pânico**

**Preparar-se para ser competitivo**

# INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE NA EUROPA

*EIP Active and Healthy Ageing*

New Knowledge

Proven Ideas

New solutions

Evidence and innovation guidelines

Deployment support

Joint Programming Initiatives

Antimicrobial Resistance

Neurodegenerative Diseases

Horizon 2020

Health

Biotechnology

Nanotechnology

ICT

eHealth

ICT & Ageing

Ambient Assisted Living (AAL2)

Public Health Programme

Structural Funds

EIB

ESF

CEF

Research

Innovation

Deployment

# A SAÚDE NO H2020



# A SAÚDE NO H2020



# OPORTUNIDADES DE FINANCIAMENTO
# DESAFIO SOCIETAL 1

# DS1 – SAÚDE, ALTERAÇÕES DEMOGRÁFICAS E BEM ESTAR

## *Better health for all*

1. *Understanding health, wellbeing and disease*
2. *Preventing disease*
3. *Treating and managing disease*
4. *Active ageing and self-management of health*
5. *Methods and data*
6. *Health care provision and integrated care*

***Orçamento (2014-2020): EUR 7.257 M***

# TÓPICOS DA SAÚDE - CARACTERÍSTICAS

- Tópicos mais **abertos**
- Foco na **inovação** e no **impacto**
- Ênfase nos **consumidores finais**
- Mais **estudos clínicos** e proximidade do mercado
- Grande investimento nas **ferramentas de ICT**
- Questões transversais (**SSH, gender aspects**)
- **Sinergias** com outros financiamentos (fundos estruturais, AAL, EDCTP, EU Health Programme, etc).
- Forte envolvimento das **PMEs** e das **entidades dos sistemas de saúde**

# PROGRAMA DE TRABALHOS DS1 2016-2017

- **Orçamento total**: **~934 M€**

- **Personalised Medicine (PM):**
  - 21 tópicos
  - 608,76 M€

- **Co-ordination Activities (HCO):**
  - 15 tópicos
  - 49,5 M€

- **SME Instrument:**
  - 2 tópicos
  - 110,5 M€

- **Other actions:** 12 tópicos



European Commission

EN

Horizon 2020

Work Programme 2016 - 2017

*8. Health, demographic change and well-being*

**Important notice on the second Horizon 2020 Work Programme**

**This Work Programme covers 2016 and 2017. The parts of the Work Programme that relate to 2017 are provided at this stage on an indicative basis. Such Work Programme parts will be decided during 2016.**

*(European Commission Decision C (2015)6776 of 13 October 2015)*

# *HIGHLIGHTS* PROGRAMA DE TRABALHOS DS1 2016-2017

***Strategic orientation - "promoting healthy ageing and personalised healthcare"***

- Personalised medicine
- Active and healthy ageing
- Human bio-monitoring
- e/mHealth (ICT)
- Infectious diseases (incl. vaccines)
- Maternal and child health

# CALL PM: Understanding health, well-being and disease

| 1.1 Understanding health, well-being and disease | | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| TOPIC | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| ● | SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system | RIA | RTD | 12-15 | 30 | 13-04-16 | |
| ● ● | SC1-PM-02-2017: New concepts in patient stratification | RIA | RTD | 4-6 | 40 | | 04-10-16 (1st phase) 11-04-17 (2nd phase) |
| | SC1-PM-03–2017: Diagnostic characterisation of rare diseases | RIA | RTD | 15 | 15 | | 11-04-17 |
| ● ● | SC1-PM-04–2016: Networking and optimising the use of population and patient cohorts at EU level | RIA | RTD | 8-10 | 30 | 13-04-16 | |
| | **TOTAL** | | | | **115** | | |

● PM ● AHA ● HBM

● ICT ● ID ● MCH

# CALL PM: Preventing disease

| 1.2 Preventing disease<br>TOPIC | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|
| | | | M€ Projecto | M€ Total | 2016 | 2017 |
| SC1-PM-05–2016: The European Human Biomonitoring Initiative | COFUND (EJP) | RTD | 50 | 50 | 13-04-16 | |
| SC1-PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases | RIA | RTD | | 40 | 13-04-16 | |
| a) Larger platforms proposals | | | 15-20 | | | |
| b) Smaller proposals | | | 3-5 | | | |
| SC1-PM-07–2017: Promoting mental healt and well-being in the young | RIA | RTD | 2-4 | 20 | | 04-10-16 (1st phase) 11-04-17 (2nd phase) |
| **TOTAL** | | | | **110** | | |

PM AHA HBM

ICT ID MCH

# CALL PM: Treating and managing diseases

| 1.3 Treating and managing diseases | | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| TOPIC | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| ● | SC1-PM-08–2017: New therapies for rare diseases | RIA | RTD | 4-6 | 60 | | 04-10-16 (1st phase) 11-04-17 (2nd phase) |
| ● ● | SC1-PM-09–2016: New therapies for chronic diseases | RIA | RTD | 4-6 | 60 | 13-04-16 | |
| ● ● | SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population | RIA | RTD | 4-6 | 40 | | 04-10-16 (1st phase) 11-04-17 (2nd phase) |
| ● | SC1-PM-11–2016-2017: Clinical research on regenerative medicine | RIA | RTD | 4-6 | 30+30 | 13-04-16 | 11-04-17 |
| | **TOTAL** | | | | **160** | | |

● PM ● AHA ● HBM
● ICT ● ID ● MCH

# CALL PM: Active ageing and self-management of health

| 1.4 Active ageing and self-management of health | | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| TOPIC | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| | SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient | COFUND (PCP) | CNECT | 3 | 18 | 16-02-16 | |
| | SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing | COFUND (PPI) | CNECT | 2-5 | 10,5 | 16-02-16 | |
| | SC1-PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities | RIA | CNECT | 1-2 | 5 | 19-01-16 | |
| | SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age | RIA | CNECT | 3-4 | 25 | | 31-01-17 |
| | **TOTAL** | | | | **58,5** | | |

PM AHA HBM

ICT ID MCH

# CALL PM: Methods and data

| 1.5 Methods and data | | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| TOPIC | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| ● | SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products | RIA | CNECT | 4-6 | 19 | | 14-03-17 |
| ● | SC1-PM-17–2017: Personalised computer models and in-silico systems for well-being | RIA | CNECT | 4-6 | 19 | | 14-03-17 |
| ● | SC1-PM-18–2016: Big Data supporting Public Health policies | RIA | CNECT | 3-5 | 10 | 16-02-16 | |
| ● | SC1-PM-19–2017: PPI for uptake of standards for the exchange of digitalised healthcare records | COFUND (PPI) | CNECT | 3-4 | 8,26 | | 14-03-17 |
| ● | SC1-PM-20-2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector | RIA | RTD | tbd | 9 | | 11-04-17 |
| | **TOTAL** | | | | **65,26** | | |

● PM ● AHA ● HBM

● ICT ● ID ● MCH

# CALL PM: Health care provision and integrated care

| TOPIC | | TYPE OF ACTION | DG | BUDGET | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| 1.6 Health care provision and integrated care | | | | | | | |
| ● | SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries | RIA | RTD | 4-6 | 40 | 13-04-16 | |
| | **TOTAL** | | | | **40** | | |

● PM ● AHA ● HBM

● ICT ● ID ● MCH

# CALL: OTHER COORDINATION ACTIONS (I)

| Other Coordination Actions<br>Topic | | TYPE OF ACTION | DG | Budget | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| | | | | M€ Projecto | M€ Total | 2016 | 2017 |
| | SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results | CSA | RTD | 1-2 | 2 | 13-04-16 | |
| ● | SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine | CSA | RTD | 2 | 2 | 13-04-16 | |
| ● | SC1-HCO-03–2017: Implementing the Strategic Research Agenda on Personalised Medicine | ERA-NET Cofund | RTD | 5 | 5 | | 11-04-17 |
| ● | SC1-HCO-04–2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance | CSA | RTD | 1-2 | 2 | 13-04-16 | |
| ● | SC1-HCO-05–2016: Coordinating personalised medicine research | CSA | RTD | 02 | 2 | 13-04-16 | |
| ● | SC1-HCO-06–2016: Towards an ERA-NET for building sustainable and resilient health system models | CSA | RTD | 1-2 | 2 | 13-04-16 | |
| | SC1-HCO-07–2017: Global Alliance for Chronic Diseases (GACD) | RIA | RTD | tbd | 24 | | 11-04-17 |
| | SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation | CSA | RTD | 1 | 1 | | 11-04-17 |

● PM ● AHA ● HBM

● ICT ● ID ● MCH

# CALL: OTHER COORDINATION ACTIONS (II)

| Other Coordination Actions<br>Topic | | TYPE OF ACTION | DG | Budget | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| | | | | Projecto | Total | 2016 | 2017 |
| | SC1-HCO-10–2016: Support for Europe's leading Health ICT SMEs | CSA | CNECT | 3 | 3 | 16-02-16 | |
| | SC1-HCO-11–2016: Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change | CSA | CNECT | 1 | 1 | 16-02-16 | |
| | SC1-HCO-12–2016: Digital health literacy | CSA | CNECT | 2 | 2 | 16-02-16 | |
| | SC1-HCO-13–2016: Healthcare workforce IT skills | CSA | CNECT | 0,5 | 0,5 | 16-02-16 | |
| | SC1-HCO-14–2016: EU-US interoperability roadmap | CSA | CNECT | 1 | 1 | 16-02-16 | |
| | SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment | CSA | CNECT | 1 | 1 | 16-02-16 | |
| | SC1-HCO-16-2016: Standardisation needs in the field of ICT for Active and Healthy Ageing | CSA | CNECT | 1 | 1 | 16-02-16 | |
| | **TOTAL** | | | | **49,5** | | |

PM AHA HBM

ICT ID MCH

# CALL: OTHER ACTIONS

| Other Actions<br>TOPIC | | TYPE OF ACTION | Budget M€ | | DEADLINE | |
|---|---|---|---|---|---|---|
| | | | 2016 | 2017 | 2016 | 2017 |
| | HOA 2 - InnovFin Infectious Diseases (InnovFin ID) Pilot | Financial Instrument | 50 | 50 | Q1 | Q1 |
| | HOA 8 - Horizon Prize on reducing maternal and new-born morbidity and mortality - the Birth Day Prize | Inducement Prize | 1 | | - | Q2 |

PM AHA HBM

ICT ID MCH

# CALL: SME INSTRUMENT

| SME Instrument<br>Topic | TYPE OF ACTION | DG | Budget | | | DEADLINE | |
|---|---|---|---|---|---|---|---|
| | | | M€ Projecto | 2016 | 2017 | Fase 1 | Fase 2 |
| **SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector** | SME | RTD | | **35** | **45** | | |
| a) Cell technologies in medical applications | | | Fase 1: 50.000 €; Fase 2: 1-5M€ | 35 | 35 | 24-02-16<br>03-05-16<br>07-09-16<br>09-11-16<br>-<br>15-02-17<br>03-05-17<br>06-09-17<br>08-11-17 | 03-02-16<br>14-04-16<br>15-06-16<br>13-10-16<br>-<br>18-01-17<br>06-04-17<br>01-06-17<br>18-10-17 |
| b) Clinical research for the validation of biomarkers and/or diagnostic medical devices | | | Fase 2: 1-5M€ | 0 | 10 | - | 15-02-17 |
| **SMEInst-06-2016-2017: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well** | SME | CNECT | Fase 1: 50.000 €; Fase 2: 1-5M€ | **18** | **12,5** | 24-02-16<br>03-05-16<br>07-09-16<br>09-11-16<br>-<br>15-02-17<br>03-05-17<br>06-09-17<br>08-11-17 | 03-02-16<br>14-04-16<br>15-06-16<br>13-10-16<br>-<br>18-01-17<br>06-04-17<br>01-06-17<br>18-10-17 |
| **TOTAL** | | | | **53** | **57,5** | | |

*Continuously open call H2020-SMEInst-2016-2017, Horizon 2020 Work Programme Part – Innovation in SMEs*

# INICIATIVAS ESTRATÉGICAS SAÚDE

Innovative Medicines Initiative

Innovative Medicines Initiative 2
www.imi.europa.eu

ropean Innovation Partnership on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha

AAL
AMBIENT ASSISTED LIVING

Active and Assisted Living 2
www.aal-europe.eu

E D C

European & Developing Countries Clinical Trials Partnership (EDCTP2)
www.edctp.org

**Elisabete Pires**
elisabete.pires@fct.pt

**Ricardo Pereira**
ricardo.pereira@fct.pt

# INICIATIVA DOS MEDICAMENTOS INOVADORES (IMI2)

- Iniciativa Tecnológica Conjunta entre a **União Europeia** e a **EFPIA**
- Objectivos do IMI2 com base na Strategic Research Agenda (SRA):

1. A 30% better success rate in **clinical trials of priority medicines** identified by the WHO;
2. Clinical proof of concept in **immunological, respiratory, neurological and neurodegenerative diseases** in just five years;
3. New and approved **diagnostic markers** for four of these diseases and at least two **new medicines** which could either be new **antibiotics** or new therapies for **Alzheimer's disease**.

**ORÇAMENTO TOTAL IMI2 (2014-2024): 3.276 M€**
**(1.638 M€ H2020 + 1.425 M€ EFPIA (*in kind*) + 213 M€ indústrias das ciências da vida)**

# IMI2 – 6TH CALL FOR PROPOSAL (2-stage)

DEADLINE 12 January 2016

- **Topic 1**: Development of a quantitative **system toxicology** (
- **Topic 2:** Establishing impact of **RSV infection**, resultant **disease and public health approach** to reducing the consequences

***Topics under the IMI programme Big Data for Better Outcomes*:**

- **Topic 3:** Real World Outcomes Across the **AD Spectrum** (ROADS) to **Better Care**
- **Topic 4**: Development of an outcomes focused informatics platform to **empower policy makers** and **clinicians** to optimize **care for patients with hematologic malignancies**

# IMI2 – 7TH AND 8TH CALL FOR P[illegible]OSALS

DEADLINE 15 March 2016 (?)

- **Ebola** and other **filoviral haemorrhagic fevers** (Ebo[illegible]
- Validation of translational **imaging methods in drug safety asses**[illegible]
- Identification of **drugable targets** modulating **misfolded proteins** in major **neurodeg**[illegible]**tive** diseases
- Pathological **neuron-glia interactions** in **neuropathic pain**
- **Dry age-related macular degeneration**: development of **novel clinical endpoints** for clinical trials with a regulatory and patient access intention
- A comprehensive '**paediatric preclinical POC platform**' to enable clinical molecule development for **children with cancer**
- Identification and validation of **non-invasive markers** across the spectrum of **nonalcoholic fatty liver disease** (NAFLD)

***Topics under the Big Data for Better Outcomes programme***

- Coordination and support action (CSA) for the **big data for better outcomes programme**
- Increase access and use of **high quality data** to improve **clinical outcomes in heart failure** (HF), **atrial fibrillation** (AF), and **acute coronary syndrome** (ACS) patients

# NCPs Saúde:

**Saúde**
**IMI**

Patrícia Calado

patricia.calado@gppq.pt

+351 91 183 64 53

**Questões legais e financeiras | Saúde**
**IMI**
**EDCTP**

Sandra Fernandes

sandra.fernandes@gppq.pt

+351 21 391 76 48

# OPORTUNIDADES DE FINANCIAMENTO
# DESAFIO SOCIETAL 2

# 5 grandes atividades no Programa Específico do DS2

**Agricultura e silvicultura**

**Sector Agro-alimentar**

**Aquicultura e pescas**

**Bioindústrias e bioeconomia**

**Investigação marinha e marítima**

http://ec.europa.eu/programmes/horizon2020/en/h2020-section/food-security-sustainable-agriculture-and-forestry-marine-maritime-and-inland-water

**17 Fev2016 | 14 Fev 2017**
**two-stage topics**

| *'Sustainable Food Security' call (SFS)* | *2016* | *2017* |
|---|---|---|
| SAFE AND HEALTHY DIETS AND SUSTAINABLE CONSUMPTION | | |
| **SFS-37:** The **impact of consumer practices in food safety:** risks and mitigation strategies (RIA, 9,5M€) | X | |
| **SFS-38: Impulsivity and compulsivity and the link to nutrition**, lifestyle and the socio-economic environment (RIA, 12M€ ) | X | |
| **SFS-39:** How to tackle the **childhood obesity epidemic** (RIA, 10M€) | | X |
| **SFS-40: Sweeteners** and sweetness enhancers (RIA, 9M€) | | X |

# PILLAR 2: *Healthy oceans and seas for healthy people*

→ O objetivo é explorar a **interação entre os oceanos e a saúde humana**

**14 Fev2017**
**One-stage topics**

| *Healthy oceans and seas for healthy people* | *2016* | *2017* |
|---|---|---|
| **BG-6: Interaction between humans, oceans and seas**: a strategic approach towards healthcare and wellbeing (CSA, 2M€) | | X |
| **BG-8:** Innovative sustainable solutions for improving the **safety and dietary properties of seafood** (IA, 7M€) | | X |

# NCPs Bioeconomia:

**Bio Economia**
**BBI**
**Biotecnologia**

Maria João Fernandes

**GPPQ**

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

mariajoao.fernandes@fct.pt

+351 91 841 79 20


**Bio Economia**

José Antão

jose.antao@gppq.pt

+351 21 391 76 48

# OPORTUNIDADES DE FINANCIAMENTO NMBP

# *Call for Nanotechnologies, Advanced materials, Biotechnology and Production*

**Áreas Temáticas 2016/2017**

1. Materiais avançados e nanotecnologia para **produtos de elevado valor acrescentado e indústria de processos**
2. Materiais Avançados e Nanotecnologias para os **Cuidados de Saúde**
3. Materiais Avançados e Nanotecnologias para **a Energia**
4. ***Eco-design*** e novos **modelos de negócio sustentáveis**
5. **Biotecnologia**
6. **Modelação para o desenvolvimento** de nanotecnologias e materiais avançados
7. **Avaliação e Gestão do risco** das nanotecnologias, materiais avançados e biotecnologias
8. **Governância inovadora e responsável** de tecnologias facilitadoras novas e convergentes

# Nanotecnologia e materiais avançados para Cuidados de Saúde mais eficazes

| Tópico | Ação | Cont. EC/proj |
|---|---|---|
| **NMBP-09-2016:** Biomaterials for **diagnosis and treatment of demyelination disorders of the Central Nervous System** | **RIA** | 5 – 8 M€ |
| **NMBP-10-2016: Nanoformulation of biologicals** | **RIA** | 5 – 6 M€ |
| **NMBP-12-2017:** Development of a reliable methodology for **better risk management of engineered biomaterials** in Advanced Therapy Medicinal Products and/or Medical Devices | **RIA** | 5 – 8 M€ |
| **NMBP-14-2017:** Regulatory Science Framework for assessment of **risk benefit ratio** of Nanomedicines and Biomaterials | **RIA** | 5 – 8 M€<br>Apenas 1 projeto financiado |
| **NMBP-15-2017:** Nanotechnologies for **imaging cellular transplants and regenerative processes in vivo** | **RIA** | 5 – 7 M€ |
| **NMBP-13-2017:** Cross-cutting **KETs for diagnostics at the point-of-care** | **RIA** | **3 – 5 M€** |
| **NMBP-16-2017: Mobilising the European nano-biomedical ecosystem** | **CSA** | **1-2 M€** |

# Biotecnologia

- Desenvolvimento de produtos e processos industriais competitivos, sustentáveis, seguros e inovadores;
- Funciona como motor de inovação em vários setores europeus, como a agricultura, a silvicultura, a alimentação, a energia, os produtos químicos e a **saúde**, assim como a bioeconomia.

| Tópico | TRL | Ação | Contr. EC/proj |
|---|---|---|---|
| **BIOTEC-03-2016: Microbial chassis platforms** with optimized metabolic pathways for **industrial innovations through systems biology** SMEs encouraged | **3 → 5** | **RIA** | 5 – 7 M€ |
| **BIOTEC-04-2016: KET Biotechnology foresight** identifying gaps and high-value **opportunities for the EU industry** | | **CSA** | 350 – 500 K€ Apenas 1 projeto financiado |

**RIA: 8 Dez 2015 | 24 Maio 2016**
**CSA: 21 Jan 2017**

# NCPs NMBP:

**NMP+B**
**Apoio a PME**
**Fast Track**

Marta Candeias

**GPPQ**

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

marta.candeias@fct.pt

+351 93 200 38 41

**NMP+B**
**RFCS**

Sofia Azevedo

**GPPQ**

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

sofia.azevedo@fct.pt

+351 93 929 09 20

**Bio Economia**
**BBI**
**Biotecnologia**

Maria João Fernandes

**GPPQ**

Av. D. Carlos I, nº126, 4º andar
1249-074 LISBOA

mariajoao.fernandes@fct.pt

+351 91 841 79 20

Orientações para a preparação de uma proposta em colaboração

# COMO COMEÇAR?

- Ideia **clara** para um projeto
- Consistente com o **tópico** do programa de trabalhos
- **Inovadora** e com potencial de **exploração**
- Para além do **estado-da-arte**
- Dimensão **Europeia**!

# IDENTIFICAR TÓPICOS DE INTERESSE

## Procurar no Participant Portal….



# IDENTIFICAR TÓPICOS DE INTERESSE

## …ou estudar o Programa de Trabalhos!

EN

HORIZON 2020

WORK PROGRAMME 2014 – 2015

*8. Health, demographic change and wellbeing*

*Revised*

This Work Programme was adopted on 10 December 2013. The parts that relate to 2014 (topics, dates, budget) have, with this revised version, been updated. The changes relating to this revised part are explained on the Participant Portal.

*(European Commission Decision C (2014)4995 of 22 July 2014)*

# PREPARAÇÃO DA PROPOSTA

## Parte A - Informação Administrativa:

apenas formulários online!...incluindo abstract

## Parte B - Informação Técnica:

upload de PDF numa determinada estrutura




http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/2016-2017/h2020-call-pt-ria-ia-2016-17_en.pdf

# PARTE A – INFORMAÇÃO ADMINISTRATIVA

- Preenchimento **online**
- **Informação geral**
  título, duração, palavras-chave, sumário
- **Dados administrativos** da organização parceira
- **Orçamento global** da proposta e de cada organização **parceira**



# PARTE B – INFORMAÇÃO TÉCNICA

**1. Excellence**
- 1.1 Objectives
- 1.2 Relation to the work programme
- 1.3 Concept and approach
- 1.4 Ambition

**2. Impact**
- 2.1 Expected impacts
- 2.2 Measures to maximise impact
  - a) Dissemination and exploitation of results
  - b) Communication activities

**3. Implementation**
- 3.1 Work plan — Work packages, deliverables and milestones
- 3.2Management structure and procedures
- 3.3 Consortium as a whole
- 3.4 Resources to be committed

**4. Members of the consortium**
- 4.1 Participants (applicants)
- 4.2 Third parties involved in the project (including use of third pa

**5. Ethics and Security**
- 5.1Ethics
- 5.2 Security

**Max 70 páginas!**



*Please refer to submission system for the definitive template for your call*

1. **Excellence**

**Your proposal must address a topic set out in the work programme, for this call for proposals.**

*This section of your proposal will be assessed only to the extent that it is relevant to that topic.*

1.1 **Objectives**

- Describe the specific objectives for the project[1], which should be clear, measurable, realistic and achievable within the duration of the project. Objectives should be consistent with the expected exploitation and impact of the project (see section 2).

1.2 **Relation to the work programme**

- Indicate the work programme topic to which your proposal relates, and explain how your proposal addresses the specific challenge and scope of that topic, as set out in the work programme.

1.3 **Concept and approach, quality of the coordination and support measures**

- Describe and explain the overall concept underpinning the project. Describe the main ideas, models or assumptions involved;
- Describe any national or international research and innovation activities which will be linked with the project, especially where the outputs from these will feed into the project;
- Describe and explain the overall approach, distinguishing, as appropriate, coordination and support activities;
- Where relevant, describe how sex and/or gender analysis is taken into account in the project's content.

*Sex and gender refer to biological characteristics and social/cultural factors respectively. For guidance on method: of sex / gender analysis and the issues to be taken into account, please refer to http://ec.europa.eu/research/science-society/gender-in-innovation/index_en.cfm*

[1] The term 'project' used in this template equates to an 'action' in certain other Horizon 2020 documentation.

Example, not to complete

# CRITÉRIOS DE AVALIAÇÃO



# PROPOSTAS H2020 – ABORDAGEM INTEGRADA

Painel de Avaliação

- soluções para o problema
- inovadora
- viável nas metas propostas
- competências e complementaridade no consórcio
- dimensão Europeia
- bem orçamentada
- estrutura de gestão adequada à dimensão do consórcio e complexidade da proposta

# FERRAMENTAS DE PROCURA DE PARCEIROS EU E PT

Congressos/conferências

*Infodays UE*

Ferramentas virtuais

Projetos financiados
(>1000 entre 2007-2013)

Redes profissionais

**H2020 Health European Brokerage Event**

*Partnering for PHC 2015 calls*

**Proposta convincente**

**Consórcio sólido**

**Ideia**

# GPPQ – Gabinete de Promoção do Programa-Quadro

## www.gppq.pt/h2020/

**Verifique o calendário das sessões de divulgação e workshops sobre escrita de propostas**

http://www.gppq.pt/h2020/contactos_ncp.php